Flow Traders U.S.’s Franklin Genomic Advancements ETF HELX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-6,488
Closed -$315K 872
2021
Q4
$315K Hold
6,488
0.02% 597
2021
Q3
$339K Sell
6,488
-225
-3% -$12.2K 0.01% 802
2021
Q2
$348K Hold
6,713
0.02% 697
2021
Q1
$291K Buy
+6,713
New +$314K 0.02% 656

Other funds holding HELX

Flow Traders U.S.'s HELX Position: Q1 2022 in Review

Flow Traders U.S. sold out of Franklin Genomic Advancements ETF (HELX) in Q1 2022, closing a stake of 6,488 shares — an estimated $315K sold.

Flow Traders U.S. first reported a position in HELX in Q1 2021 and held it in 4 quarters. The position peaked at $348K in Q2 2021. 8 funds tracked by Wall St. Rank hold HELX as of Q1 2022.

  • Flow Traders U.S. reported no remaining Franklin Genomic Advancements ETF position as of Q1 2022 after selling out during the quarter.
  • Flow Traders U.S. sold 6,488 Franklin Genomic Advancements ETF shares in Q1 2022, an estimated $315K.
  • Flow Traders U.S. first reported a position in Franklin Genomic Advancements ETF in Q1 2021 and held it in 4 quarters.
  • Flow Traders U.S.'s Franklin Genomic Advancements ETF position peaked at $348K in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q1 2022.

Based on Flow Traders U.S.'s 13F filing for Q1 2022, filed 13 May 2022.